tiprankstipranks
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
PremiumPress ReleasesCogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
2M ago
3 Best Stocks to Buy Now, 5/8/2024, According to Top Analysts 
PremiumMarket News
3 Best Stocks to Buy Now, 5/8/2024, According to Top Analysts 
3M ago
Cogent Biosciences reports Q1 EPS (62c), consensus (52c)
PremiumThe Fly
Cogent Biosciences reports Q1 EPS (62c), consensus (52c)
3M ago
Cogent Biosciences price target raised to $19 from $13 at H.C. Wainwright
PremiumThe FlyCogent Biosciences price target raised to $19 from $13 at H.C. Wainwright
5M ago
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
5M ago
Cogent Biosciences expects cash to fund requirements into 2027
PremiumThe Fly
Cogent Biosciences expects cash to fund requirements into 2027
5M ago
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
PremiumPress ReleasesCogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
5M ago
Cogent Biosciences announces ‘positive’ Part 1b data from SUMMIT trial
PremiumThe Fly
Cogent Biosciences announces ‘positive’ Part 1b data from SUMMIT trial
5M ago
Cogent Biosciences Launches $225M Private Stock Sale
PremiumCompany Announcements
Cogent Biosciences Launches $225M Private Stock Sale
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100